title: Genetic immunotherapy by intrapleural, intraperitoneal and subcutaneous injection of IL-2 gene-modified Lewis lung carcinoma cells.
abstract: The induction and augmentation of tumor non-specific immunity and of tumor-specific immunity by intrapleural, intraperitoneal and subcutaneous injection of interleukin-2 (IL-2) gene-modified Lewis lung carcinoma (LLC) cells (LLC-IL2) was tested in C57BL/6 mice. Intrapleural injection of LLC cells induced lung tumors with a malignant effusion, intraperitoneal injection induced peritoneal tumors with ascites and subcutaneous injection induced subcutaneous tumors. Intrapleural injection of irradiated LLC-IL2 cured pre-existing lung LLC tumors and extended the survival of the mice but did not affect survival of mice with pre-existing peritoneal tumors nor did it affect the growth of s.c. tumors. Intraperitoneal injection of irradiated LLC-IL2 cured pre-existing LLC peritoneal tumors and extended the survival of the mice but did not affect survival of mice bearing lung tumors nor did it affect the growth of s.c. tumors. Subcutaneous injection of irradiated LLC-IL2 did not affect the growth of preexisting s.c. tumors and also did not improve survival of mice bearing the lung or peritoneal tumors. Injection with irradiated LLC-IL2 by all routes, i.e., intrapleural, intraperitoneal and s.c., protected against subsequent re-challenge with LLC. Eight days after the initial immunization (early stage of immunization), non-adherent mononuclear cells in the peritoneal cavity of the mice treated with intraperitoneal injection of irradiated LLC-IL2 displayed enhanced cytotoxicity against LLC, B16-F10 and P815 cells, while the cytotoxic activity of spleen cells in the same mice did not change. The efficiency of induction of tumor-specific immunity was the strongest after intraperitoneal immunization and weakest after s.c. immunization. In vitro analysis using the spleen cells of mice immunized with irradiated LLC-IL2 suggested that CD8+ T cells play a key role in tumor-specific immunity.
authors.affiliation: Pharmacology Division, National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Heike
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Ohira
authors.forename: I
authors.initials: I
authors.lastname: Naruse
authors.forename: S
authors.initials: S
authors.lastname: Hama
authors.forename: Y
authors.initials: Y
authors.lastname: Ohe
authors.forename: T
authors.initials: T
authors.lastname: Kasai
authors.forename: H
authors.initials: H
authors.lastname: Fukumoto
authors.forename: K J
authors.initials: KJ
authors.lastname: Olsen
authors.forename: E E
authors.initials: EE
authors.lastname: Podack
authors.forename: N
authors.initials: N
authors.lastname: Saijo
mesh_terms: D000818:Animals; D001201:Ascites; D018827:Carcinoma, Lewis Lung / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D003602:Cytotoxicity, Immunologic; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000235:genetics*; D051379:Mice; D008810:Mice, Inbred C57BL; D010534:Peritoneal Neoplasms / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D012878:Skin Neoplasms / Q000276:immunology / Q000401:mortality / Q000517:prevention & control / Q000628:therapy*; D015996:Survival Rate; D014162:Transfection; D014407:Tumor Cells, Cultured; D014611:Vaccination / Q000379:methods
chemical_list: D007376:Interleukin-2